Skip to content
Disclosery

Merck & Co., Inc.

Follow

13F filer, CIK 310158, RAHWAY, NJ

Merck & Co., Inc. reported $276,276,803 across 12 holdings for the quarter ended 2025-12-31, in a 13F-HR filed 2026-02-17. Its ten largest share positions make up 99.98% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000310158-26-000055

Period
2025-12-31
Reported value
$276M
Holdings
12
Top 10 weight
99.98%
New
0
Sold out
1

Part of the filer group Merck & Co., Inc.

How groups are built

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
SUTRO BIOPHARMA INCreduced-2,451,158-$28.4M
LAVA THERAPEUTICS NVexited-1,149,345-$1.79M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2025

Share positions as resolved from 13F-HR 0000310158-26-000055, largest first. % of portfolio is the value over $276,276,803, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PSNLPERSONALIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 14,044,943 shares; 2025Q1: 14,044,943 shares; 2025Q2: 14,044,943 shares; 2025Q3: 14,044,943 shares; 2025Q4: 14,044,943 shares 14,044,943$112M40.47%0Timeline
MRNAMODERNA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 2,308,190 shares; 2025Q1: 2,308,190 shares; 2025Q2: 2,308,190 shares; 2025Q3: 2,308,190 shares; 2025Q4: 2,308,190 shares 2,308,190$68.1M24.64%0Timeline
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 772,165 shares; 2025Q1: 772,165 shares; 2025Q2: 772,165 shares; 2025Q3: 772,165 shares; 2025Q4: 772,165 shares 772,165$60.1M21.75%0Timeline
ENTRADA THERAPEUTICS INCENTRADA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,739,768 shares; 2025Q1: 1,739,768 shares; 2025Q2: 1,739,768 shares; 2025Q3: 1,739,768 shares; 2025Q4: 1,739,768 shares 1,739,768$17.9M6.47%0
EVAXION BIOTECH A/SEVAXION BIOTECH A/SQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 542,279 shares; 2025Q1: 1,214,126 shares; 2025Q2: 1,214,126 shares; 2025Q3: 1,214,126 shares; 2025Q4: 1,214,126 shares 1,214,126$5.79M2.1%0
ALECALECTOR INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 3,545,719 shares; 2025Q1: 3,545,719 shares; 2025Q2: 3,545,719 shares; 2025Q3: 3,545,719 shares; 2025Q4: 3,545,719 shares 3,545,719$5.53M2%0Timeline
SUTRO BIOPHARMA INCSUTRO BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 2,723,509 shares; 2025Q1: 2,723,509 shares; 2025Q2: 2,723,509 shares; 2025Q3: 2,723,509 shares; 2025Q4: 272,351 shares 272,351$3.15M1.14%-2,451,158
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 93,414 shares; 2025Q1: 93,414 shares; 2025Q2: 93,414 shares; 2025Q3: 93,414 shares; 2025Q4: 93,414 shares 93,414$2.91M1.05%0Timeline
XLOXilio Therapeutics Inc.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,483,758 shares; 2025Q1: 1,483,758 shares; 2025Q2: 1,483,758 shares; 2025Q3: 1,483,758 shares; 2025Q4: 1,483,758 shares 1,483,758$950K0.34%0Timeline
CARMCARISMA THERAPEUTICS INC COMQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,473,240 shares; 2025Q1: 1,473,240 shares; 2025Q2: 1,473,240 shares; 2025Q3: 1,473,240 shares; 2025Q4: 1,473,240 shares 1,473,240$63.3K0.02%0Timeline
NEUPNEUPHORIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 10,027 shares; 2025Q1: 10,027 shares; 2025Q2: 10,027 shares; 2025Q3: 10,027 shares; 2025Q4: 10,027 shares 10,027$38.9K0.01%0Timeline
HURATUHURA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 13,950 shares; 2025Q3: 13,950 shares; 2025Q4: 13,950 shares 13,950$10.6K<0.01%0Timeline

Sold out in Q4 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
LAVA THERAPEUTICS NVLAVA THERAPEUTICS NV1,149,345$1.79Mshares

How Q4 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000310158-26-000055 base2026-02-17acceptance time not in the bulk data set